<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03194945</url>
  </required_header>
  <id_info>
    <org_study_id>2016146</org_study_id>
    <nct_id>NCT03194945</nct_id>
  </id_info>
  <brief_title>Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes</brief_title>
  <official_title>Effects of Linagliptin and Metformin Monotherapy or Combined Sequential Treatment After Early Short-term Intensive Insulin Treatment on Long-term Blood Glucose Control and Function of β Cells in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Affiliated Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Short-term intensive insulin therapy(SIIT) is able to reverse β cell dysfunction and induce&#xD;
      glycemic remission in patients with newly diagnosed type 2 diabetes. However, proportion of&#xD;
      patients with response gradually decreases over time. There is no consensus on which&#xD;
      treatment should be given in order to maintain the benefit in glycemic control and β cell&#xD;
      recovery. In this multi-center, randomized, controlled study, effects of various sequential&#xD;
      treatments ( metformin, linagliptin and combined with both drugs) on long-term blood glucose&#xD;
      control as well as preservation of β cell function after SIIT were investigated.&#xD;
&#xD;
      In total, 448 patients with newly diagnosed type 2 diabetes who meet the inclusive criteria&#xD;
      will be enrolled in eight centers in China. After baseline assessments, all patients will be&#xD;
      treated with insulin pump to achieve and maintain euglycemia for 2 weeks. After completion of&#xD;
      intensive treatment, insulin pump will be stopped. Different treatments will be applied to&#xD;
      patients for 48 weeks according to randomization: Group A: Linagliptin 5 mg Qd + Metformin&#xD;
      0.5 g bid; Group B: Linagliptin 5 mg Qd; Group C: Metformin 0.5 g bid; Group D: No oral&#xD;
      drugs. Primary endpoint is proportion of patients achieving glycosylated hemoglobin A1C &lt;7%&#xD;
      at the end of the study. Secondary endpoints include proportion of patients achieving&#xD;
      glycosylated hemoglobin A1C &lt;6.5% at the end of study; differences in β-cell function ,&#xD;
      insulin sensitivity, GLP-1 and glucagon secretion among treatment groups, and differences in&#xD;
      adverse events among treatment groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of subjects with optimal glycemic control</measure>
    <time_frame>48 weeks</time_frame>
    <description>proportion of patients achieving glycosylated hemoglobin A1C &lt;7% at the end of sequential treatment in each treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of subjects with excellent glycemic control</measure>
    <time_frame>48 weeks</time_frame>
    <description>proportion of patients achieving glycosylated hemoglobin A1C &lt;6.5% at the end of sequential treatment in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of β cell function</measure>
    <time_frame>48 weeks</time_frame>
    <description>Differences in β-cell indicators among treatment arms at the end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of insulin sensitivity</measure>
    <time_frame>48 weeks</time_frame>
    <description>Differences in insulin sensitivity indicators among treatment arms at the end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>48 weeks</time_frame>
    <description>Differences in incidence of adverse events among treatment arms at the end of study.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">448</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Linagliptin plus metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CSII followed by Linagliptin 5 mg Qd + Metformin 0.5 g bid for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CSII followed by Linagliptin 5mg Qd for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CSII followed by Metformin 0.5 bid for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifestyle alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No OHA is given after CSII</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSII followed by Lina+MET</intervention_name>
    <description>short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks</description>
    <arm_group_label>Linagliptin plus metformin</arm_group_label>
    <other_name>CSII+Lina+Met</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSII followed by Lina</intervention_name>
    <description>short-term intensive CSII followed by Linagliptin 5mg qd for 48 weeks</description>
    <arm_group_label>Linagliptin</arm_group_label>
    <other_name>CSII+Lina</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSII followed by MET</intervention_name>
    <description>short-term intensive CSII followed by Metformin 0.5g bid for 48 weeks</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>CSII+Met</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSII alone</intervention_name>
    <description>No OHA is given after short-term intensive CSII</description>
    <arm_group_label>Lifestyle alone</arm_group_label>
    <other_name>CSII</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with type 2 diabetes who have never received any hypoglycemic treatment, or&#xD;
             patients with type 2 diabetes &lt;1 year from diagnosis who have used no more than 1 type&#xD;
             of hypoglycemic drug for no more than 1 week and discontinued for more than 4 weeks&#xD;
             before enrollment;&#xD;
&#xD;
          2. Fasting plasma glucose (FPG) between 7.0 mmol/l (126 mg/dl) and 16.7 mmol/l (300&#xD;
             mg/dl); glycosylated hemoglobin A1C&gt;8.5%;&#xD;
&#xD;
          3. Aged between 25 and 65 years, body mass index (BMI) 22-35 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1 diabetes or special type of diabetes;&#xD;
&#xD;
          2. Acute complications of diabetes (including DKA, HHS and lactic acidosis)&#xD;
&#xD;
          3. Serious microvascular complications: proliferative stage of retinopathy; urine AER&#xD;
             &gt;300 mg/g or urine protein positive, quantification &gt;0.5 g/d; uncontrolled painful&#xD;
             diabetic neuropathy and significant diabetic autonomic neuropathy;&#xD;
&#xD;
          4. Severe macrovascular complications: acute cerebrovascular accident, acute coronary&#xD;
             syndrome, vascular intervention for peripheral arterial disease or amputation&#xD;
             requiring hospitalization within 12 months prior to enrollment;&#xD;
&#xD;
          5. Persistently increased blood pressure &gt;180/110 mmHg;&#xD;
&#xD;
          6. Blood creatinine clearance less than 50 ml/min, alanine aminotransferase ≥2.5×upper&#xD;
             limit of normal, total bilirubin ≥1.5×upper limit of normal;&#xD;
&#xD;
          7. Hemoglobin &lt;100 g/L or need regular blood transfusion;&#xD;
&#xD;
          8. Use of drugs that may influence blood glucose within 12 weeks;&#xD;
&#xD;
          9. Systemic infection or serious concomitant disease; patients with malignancy or chronic&#xD;
             diarrhea;&#xD;
&#xD;
         10. Uncontrolled endocrine gland dysfunction;&#xD;
&#xD;
         11. Patients with mental or communication disorders;&#xD;
&#xD;
         12. Chronic cardiac insufficiency, heart function class III and above;&#xD;
&#xD;
         13. Pregnant women, lactating women and women of child bearing age who are not willing to&#xD;
             take contraception during the study;&#xD;
&#xD;
         14. Subjects who don't cooperate, cannot be followed up or have difficulty in completing&#xD;
             the study considered by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liehua Liu, PHD</last_name>
    <phone>+8613751748843</phone>
    <email>turkey310@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>endocrinology department of the first affiliated hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanbing Li, MD,PhD</last_name>
      <phone>8602087334331</phone>
      <email>easd04lyb@126.com</email>
    </contact>
    <investigator>
      <last_name>Yanbing Li, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yanbing Li</investigator_full_name>
    <investigator_title>Director of Endocrinology and Metabolism Department</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Continuous subcutaneous insulin infusion</keyword>
  <keyword>Metformin</keyword>
  <keyword>Linagliptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

